AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$ARTV

Banerjee Subhashis sold $8K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 1,099 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 on 2026-10-05.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Oct 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

Small insider sell, limited market impact.

02

Market read

Minor insider sale with negligible trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing may drive the transaction.

Relevance 3/10Novelty 3/10Timing: post-market filing

Background

SEC Form 4 filing discloses an insider transaction by Artiva Biotherapeutics' CMO.

Company-level read

Ticker impact

$ARTVBearishHigh confidence
Context

Chief Medical Officer sold 1,099 shares for $7,514, a small insider sale.

Expected impact

likely modest pressure as market prices in the insider sale

Evidence & confidence

The sale is small ($7.5k) and may be interpreted as a lack of confidence, but size limits impact.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine and not signal any negative outlook.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm listed on NASDAQ (ARTV).

  • Person
    Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min